Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.-Reference-Cited by-同舟云学术

Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:4502-4502
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Plimack Elizabeth R.¹,Bellmunt Joaquim²,Gupta Shilpa³,Berger Raanan⁴,Montgomery Robert B.⁵,Heath Karl⁶,Juco Jonathan⁶,Emancipator Kenneth⁶,Pathiraja Kumudu⁶,Lunceford Jared K.⁶,Perini Rodolfo F.⁶,O'Donnell Peter H.⁷

Affiliation:

1. Director, Genitourinary Clinical Research Fox Chase Cancer Center, Philadelphia, PA

2. Director, Bladder Cancer Center Dana-Farber Cancer Institute, Boston, MA

3. Department of Genitourinary Oncology H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

4. Director, Division of Medical Oncology Sheba Medical Center, Tel Hashomer, Israel

5. University of Washington Oncology, Seattle, WA

6. Merck & Co., Inc., Kenilworth, NJ

7. The University of Chicago, Chicago, IL

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.4502

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?;Molecular Diagnosis & Therapy;2023-10-24

2. Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis;Frontiers in Oncology;2023-04-14

3. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors;Journal for ImmunoTherapy of Cancer;2023-01

4. Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the ‘Real-Life’ Setting;Pharmaceuticals;2022-09-16

5. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma;Frontiers in Immunology;2022-01-11